Press Releases

Sedana Medical AB (publ) announces today that its CFO, Johan Spetz, has decided to leave the company to pursue a new career opportunity outside of the Life Science industry. Johan Spetz has held his position since March 2022. “Johan has been a key...

Sedana Medical AB (publ) announces that the company has completed its pre-NDA meeting with FDA and reached broad alignment with the Agency on the contents of the New Drug Application (NDA). FDA confirmed that safety and efficacy data from the clinical...

Improved EBITDA performance amid Q3 market headwinds Third quarter 2025 January-September 2025 CEO comments Improved EBITDA performance amid Q3 market headwinds In Q3, sales growth was modest at 7%, primarily reflecting very low ICU occupancy in several...

According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2026 shall be composed of members appointed by the three largest shareholders, along with...

Sedana Medical AB (publ) plans to present its interim report for the third quarter of 2025 on Friday October 24 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the third quarter 2025 on Friday...

Promising US data and strong sales growth in Q2 Second quarter 2025 January-June 2025 CEO comments Promising US data and strong sales growth in Q2 The first half of 2025 has been a successful period for Sedana Medical, with two record quarters in sales...

Sedana Medical AB (publ) announces that the results of the company’s paediatric study IsoCOMFORT (SED002) have been published in The Lancet Respiratory Medicine. “The publication in The Lancet Respiratory Medicine is a recognition for the...

Sedana Medical AB (publ) plans to present its interim report for the second quarter of 2025 on Friday July 18 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the second quarter 2025 on Friday July...

Sedana Medical AB (publ) announces that both of the company’s pivotal US studies, INSPiRE-ICU 1 and INSPiRE-ICU 2, have shown a greater reduction of opioid doses compared to the control group and have therefore met their first key secondary endpoint...

Sedana Medical AB’s annual general meeting was held on Thursday, 15 May 2025 and the main resolutions passed were the following. Regarding full details of the resolutions, referral is made to the notice convening the general meeting and the complete...